Ann: Invex Granted Type C Meeting with FDA, page-51

I’m just hoping that management won’t capital raise if the FDA comes back with two trials. That plus the fact that a whole slab of shares come out of escrow in the next month worries me.

I think the FDA hasn’t realised the anger they will invoke from American patients if European patients get Presendin several years before them.

Young, female patients suffering from terrible headaches and losing their vision, whilst the EU has a safe and effective drug because they backed an orphan drug developer. I would think several patients will self fund it without reimbursement...

Invex needs to do a better job of harnessing their patient voices to start the advocating to the FDA if the suggested trials don’t go their way.